-
1
-
-
69549118227
-
-
LeWitt P. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease, 88. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p325-384.
-
LeWitt P. The pharmacology of levodopa in treatment of Parkinson disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease, Vol.88. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p325-384.
-
-
-
-
2
-
-
0020059227
-
Alternate day levodopa therapy in Parkinsonism
-
Koller WC. Alternate day levodopa therapy in Parkinsonism. Neurology 1982;32:324-326.
-
(1982)
Neurology
, vol.32
, pp. 324-326
-
-
Koller, W.C.1
-
3
-
-
9044226896
-
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa
-
Parkinson Study Group
-
Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45.
-
(1996)
Ann Neurol
, vol.39
, pp. 37-45
-
-
-
4
-
-
28444499344
-
Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease
-
Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005;32: 459-484.
-
(2005)
J Pharmacokinet Pharmacodyn
, vol.32
, pp. 459-484
-
-
Chan, P.L.1
Nutt, J.G.2
Holford, N.H.3
-
5
-
-
0018892695
-
Changes in neostriatal dopamine concentrations in response to levodopa infusions
-
Doller HJ, Connor JD. Changes in neostriatal dopamine concentrations in response to levodopa infusions. J Neurochem 1980;34: 1264-1269.
-
(1980)
J Neurochem
, vol.34
, pp. 1264-1269
-
-
Doller, H.J.1
Connor, J.D.2
-
6
-
-
0033546661
-
Pharmacodynamics of the long-duration response to levodopa in PD
-
Zappia M, Bosco D, Plastino M, et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 1999;53: 557-560.
-
(1999)
Neurology
, vol.53
, pp. 557-560
-
-
Zappia, M.1
Bosco, D.2
Plastino, M.3
-
7
-
-
0024829604
-
Controlled-release carbidopa/ levodopa (Sinemet 50/200 CR4): Clinical and pharmacokinetic studies
-
LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/ levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
-
(1989)
Neurology
, vol.39
, Issue.SUPPL. 2
, pp. 45-53
-
-
LeWitt, P.A.1
Nelson, M.V.2
Berchou, R.C.3
-
8
-
-
0024520481
-
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance
-
Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-212.
-
(1989)
J Neurol Neurosurg Psychiatry
, vol.52
, pp. 207-212
-
-
Cedarbaum, J.M.1
Hoey, M.2
McDowell, F.H.3
-
9
-
-
0034968037
-
The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
-
Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001;24:150-157.
-
(2001)
Clin Neuropharmacol
, vol.24
, pp. 150-157
-
-
Heikkinen, H.1
Nutt, J.G.2
LeWitt, P.A.3
-
10
-
-
0000224448
-
Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale
-
Fahn S, Marsden DM, Goldstein M, Calne DB, editors, New York: MacMillan;
-
Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden DM, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease, Vol.2. New York: MacMillan; 1987. p153-163.
-
(1987)
Recent developments in Parkinson's disease
, vol.2
, pp. 153-163
-
-
Fahn, S.1
Elton, R.L.2
-
11
-
-
0033995552
-
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
-
Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
-
(2000)
Clin Neuropharmacol
, vol.23
, pp. 75-81
-
-
Hauser, R.A.1
Friedlander, J.2
Zesiewicz, T.A.3
-
12
-
-
0025162198
-
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/ levodopa (Sinemet CR4) in Parkinson's disease
-
Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/ levodopa (Sinemet CR4) in Parkinson's disease. Neurology 1990;40:70-74.
-
(1990)
Neurology
, vol.40
, pp. 70-74
-
-
Nelson, M.V.1
Berchou, R.C.2
LeWitt, P.A.3
-
13
-
-
0028891614
-
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers
-
Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
-
(1995)
Clin Neuropharmacol
, vol.18
, pp. 46-57
-
-
Ahtila, S.1
Kaakkola, S.2
Gordin, A.3
-
14
-
-
33748934417
-
Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease
-
Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behavior of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113:1441-1448.
-
(2006)
J Neural Transm
, vol.113
, pp. 1441-1448
-
-
Müller, T.1
Erdmann, C.2
Muhlack, S.3
-
15
-
-
0028137620
-
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
-
Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
-
(1994)
J Neurol Neurosurg Psychiatry
, vol.57
, pp. 186-189
-
-
Merello, M.1
Lees, A.J.2
Webster, R.3
-
16
-
-
21544474680
-
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR
-
Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 2005;28:115-119.
-
(2005)
Clin Neuropharmacol
, vol.28
, pp. 115-119
-
-
Paija, O.1
Laine, K.2
Kultalahti, E.R.3
-
17
-
-
0034058782
-
The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
-
Piccini P, Brooks DJ, Korpela K, et al. The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
-
(2000)
J Neurol Neurosurg Psychiatry
, vol.68
, pp. 589-594
-
-
Piccini, P.1
Brooks, D.J.2
Korpela, K.3
-
18
-
-
36148978164
-
Comparison of 200 mg retarded release levodopa/carbidop - with 150 mg levodopa/carbidopa/ entacapone application: Pharmacokinetics and efficacy in patients with Parkinson's disease
-
Müller T, Ander L, Kolf K, Woitalla D, Muhlack S. Comparison of 200 mg retarded release levodopa/carbidop - with 150 mg levodopa/carbidopa/ entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 2007;114:1457-1462.
-
(2007)
J Neural Transm
, vol.114
, pp. 1457-1462
-
-
Müller, T.1
Ander, L.2
Kolf, K.3
Woitalla, D.4
Muhlack, S.5
-
19
-
-
0014082977
-
Parkinsonism: Onset, progression, and mortality
-
Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
-
(1967)
Neurology
, vol.17
, pp. 427-442
-
-
Hoehn, M.M.1
Yahr, M.D.2
|